Literature DB >> 6199886

Infantile acid maltase deficiency. II. Muscle fiber hypertrophy and the ultrastructure of end-stage fibers.

J L Griffin.   

Abstract

Infantile acid maltase deficiency (Pompe's disease, glycogenosis II) is a progressive, severe lysosomal storage disease in which skeletal and cardiac muscle fibers accumulate membrane-bound and free glycogen and are destroyed. New information in this report concerns 1) early hypertrophy of skeletal muscle fibers, 2) absence of size change as glycogen is lost, and 3) the ultrastructure of end-stage fibers empty of glycogen. Muscle fibers enlarge as they accumulate glycogen and then stay large as glycogen is lost. They are so large that, if empty fibers did in fact contain glycogen, over 80% of the muscle would be glycogen instead of 6.3-11.5% (from 37 published determinations). Fibers that have reached "empty" end-stage are shown to be more numerous than all other stages combined in biopsies from infantile acid maltase deficiency. Ultrastructurally, end-stage fibers contain much "empty" space (liquid-filled without fine structure) and various remnants and masses of altered myofibrillar and sarcoplasmic material. Many broken membranes originally enclosing glycogen in storage lysosomes are seen. A single broken membrane can enclose an area larger than the cross section area of a muscle fiber from a normal infant. The results support the proposal of Hers that the disease is due to a deficiency of the single lysosomal enzyme acid maltase. The results also support the lysosomal rupture hypothesis of Griffin, which accounts for muscle fibers being more damaged than are other cells and for the release of glycogen to the sarcoplasm.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6199886

Source DB:  PubMed          Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol        ISSN: 0340-6075


  6 in total

1.  Micropatterned substrates with physiological stiffness promote cell maturation and Pompe disease phenotype in human induced pluripotent stem cell-derived skeletal myocytes.

Authors:  Nunnapas Jiwlawat; Eileen M Lynch; Brett N Napiwocki; Alana Stempien; Randolph S Ashton; Timothy J Kamp; Wendy C Crone; Masatoshi Suzuki
Journal:  Biotechnol Bioeng       Date:  2019-06-20       Impact factor: 4.530

2.  Acid maltase deficiency: a case study and review of the pathophysiological changes and proposed therapeutic measures.

Authors:  H Isaacs; N Savage; M Badenhorst; T Whistler
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-09       Impact factor: 10.154

Review 3.  Acid alpha-glucosidase deficiency (Pompe disease).

Authors:  Tokiko Fukuda; Ashley Roberts; Paul H Plotz; Nina Raben
Journal:  Curr Neurol Neurosci Rep       Date:  2007-01       Impact factor: 5.081

4.  Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease.

Authors:  Jami C Levine; Priya S Kishnani; Y T Chen; J Rene Herlong; Jennifer S Li
Journal:  Pediatr Cardiol       Date:  2008-07-26       Impact factor: 1.655

Review 5.  Pompe disease: from pathophysiology to therapy and back again.

Authors:  Jeong-A Lim; Lishu Li; Nina Raben
Journal:  Front Aging Neurosci       Date:  2014-07-23       Impact factor: 5.750

6.  DeepNEU: Artificially Induced Stem Cell (aiPSC) and Differentiated Skeletal Muscle Cell (aiSkMC) Simulations of Infantile Onset POMPE Disease (IOPD) for Potential Biomarker Identification and Drug Discovery.

Authors:  Sally Esmail; Wayne R Danter
Journal:  Front Cell Dev Biol       Date:  2019-12-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.